9^th World Drug Delivery Summit

Biography

Biography: Andrea L Armstead

Abstract

Conventional methods used to produce nanomedicines have several challenges such as batch-to-batch reproducibility and difficulty scaling from the research bench to clincal batch volumes. Additionally, these methods are labor intensive and the compositional scope of the nanomedicines produced is limited. Our NanoAssemblr™ platform technology provides an alternative, automated, microfluidics-based approach for nanoparticle manufacture which solves challenges associated with convetional methods and enables rapid, reproducible and scalable formulation of a variety of nanomedicines. Here, we will describe the microfluidic platform and its applications in the development of a variety of nanoparticle (NP) formulations, including liposomes, dense-core lipid NP (LNP) and polymeric NP for drug delivery applications. The strategies used to tune physical attributes (size, encapsulation efficiency) and to scale the manufacture of NP at μL to 10s of L will be discussed. A case study detailing the mechanism of LNP-mediated nucleic acid delivery into primary neurons for in vitro and in vivo genetic studies will be presented.